scholarly journals Small Cell Neuroendocrine Carcinoma of the Breast: Report of a Case

2018 ◽  
Vol 2 (2) ◽  
pp. 98
Author(s):  
Ayse Parali ◽  
Afife Ozkal ◽  
Fulya Buse Gungor ◽  
Mukaddes Kubra Melemez ◽  
Betul Simsek ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Radical Mastectomy ◽  
Small Cell ◽  
Limited Information ◽  
Carcinoma Of The Breast ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Outer Quadrant ◽  
The Right ◽  
Disease Free

Small cell neuroendocrine tumor of the breast is a rare clinical condition. Although there’s limited information about this entity, it is considered to have a poor prognosis. A 44-yearold woman presented with a 5 cm mass in the lower-outer quadrant of the right breast and its tru-cut biopsy results revealed a neuroendocrine tumor. She underwent a modified radical mastectomy followed by neoadjuvant chemotherapy and radiotherapy. She remains disease-free at the end of her 6-months follow-up period.International Journal of Human and Health Sciences Vol. 02 No. 02 April’18. Page : 98-101

Adrenocorticotropin Production by a Mammary Carcinoma

1977 ◽  
Vol 35 ◽  
pp. 462-463
Author(s):  
K.S. McCarty ◽  
N.R. Wallace ◽  
W. Litaker ◽  
S. Wells ◽  
G. Eisenbarth
Keyword(s):  
Adrenocorticotropic Hormone ◽  
Small Cell ◽  
Hormone Production ◽  
Carcinoma Of The Breast ◽  
Ectopic Acth ◽  
Ultrastructural Studies ◽  
Subcutaneous Metastases ◽  
Ectopic Acth Production ◽  
The Right ◽  
Pituitary Carcinomas

The production of adrenocorticotropic hormone by non-pituitary carcinomas has been documented in several tumors, most frequently small cell carcinoma of the lung, islet cell carcinomas of the pancreas, thymomas and carcinoids. Electron microscopy of these tumors reveals typical membrane-limited "neurosecretory" granules. Confirmation of the granules as adrenocorticotropin (ACTH) requires the use of OsO4 as a primary fixative to give the characteristic cored granule appearance in conjunction with immunohistochemical demonstration of the hormone peptide. Because of the rarity of ectopic ACTH production by mammary carcinomas and the absence of appropriate ultrastructural studies in the two examples of such ectopic hormone production in the literature of which we are aware (1,2), we present biochemical and ultrastructural data from a carcinoma of the breast with apparent ACTH production.The patient had her primary tumor in the right breast in 1969. The tumor recurred as visceral and subcutaneous metastases in 1976 and again in 1977.

Treatment of Hepatic Embryonal Undifferentiated Sarcoma With Cardiothoracic Involvement

2018 ◽  
Vol 11 (4) ◽  
pp. NP199-NP202 ◽  
Author(s):  
Carlos Domínguez-Massa ◽  
Félix Serrano-Martínez ◽  
Óscar R. Blanco-Herrera ◽  
Alberto Berbel-Bonillo ◽  
Fernando Hornero-Sos ◽  
...  
Keyword(s):  
Inferior Vena ◽  
Circulatory Arrest ◽  
Tumor Resection ◽  
Vena Cava ◽  
Hepatic Tumors ◽  
Undifferentiated Sarcoma ◽  
Right Pulmonary Artery ◽  
The Right ◽  
Disease Free

Thorough study is required to decide the appropriate management of hepatic tumors in children. We present a case report of a hepatic embryonal undifferentiated sarcoma with unfavorable prognosis in a nine-year-old girl. After undergoing a detailed cancer characteristics and extension study, a two-stage surgery approach was decided. The hepatic tumor resection was the first procedure to be performed. One week later, under cardiopulmonary bypass, deep hypothermia, and circulatory arrest, thrombectomy of the inferior vena cava and right atrium was accomplished, plus thromboendarterectomy of the right pulmonary artery. During a four-year follow-up, the patient continues to be disease-free.

Carcinoembryonic Antigen (CEA) in the Follow-Up of Disease-Free Breast Cancer Patients

1982 ◽  
Vol 68 (6) ◽  
pp. 477-480 ◽  
Author(s):  
Andrea Veronesi ◽  
Renato Talamini ◽  
Serenella Longhi ◽  
Diana Crivellari ◽  
Enzo Galligioni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Patients ◽  
Relapse Rate ◽  
Patient Population ◽  
Prognostic Value ◽  
Radical Mastectomy ◽  
Breast Cancer Patients ◽  
Disease Free

Carcinoembryonic antigen (CEA) assays (2536) were performed in 380 disease-free breast cancer patients after radical mastectomy. In the 334 evaluable patients with 3 or more determinations, the overall relapse rate after a median follow-up of 29 months was 11 %. Of 203 patients with normal CEA values, 19 (9.3 %) relapsed. In the 50 patients with the highest CEA value greater than 20 ng/ml, the relapse rate was 26 %; in the 12 patients with gradually increasing CEA elevations it was 50 %. However, CEA was unable to predict recurrence in N- patients. Premastectomy N+ was significantly associated with greater than 20 ng/ml or gradually increasing CEA values, suggesting the lack of an independent prognostic value of CEA in our patient population.

Breast angiosarcoma one year after adenosquamous endometrial cancer — diagnostic pitfalls

Open Medicine ◽  
2013 ◽  
Vol 8 (1) ◽  
pp. 52-55
Author(s):  
Darko Zdravkovic ◽  
Miroslav Granic ◽  
Marija Zdravkovic ◽  
Tomislav Randjelović ◽  
Dragoljub Bilanović ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Radical Hysterectomy ◽  
Radiation Treatment ◽  
Radical Mastectomy ◽  
Outer Quadrant ◽  
Angiosarcoma Of The Breast ◽  
One Year ◽  
The Right ◽  
Postmenopausal Female ◽  
Diagnostic Pitfalls

AbstractAngiosarcoma of the breast is a rare and very aggressive tumors originated from endothelial cells lining blood vessels. We report a case of a 55-year-old postmenopausal female with a primary breast angiosarcoma diagnosed just a one year after radical hysterectomy and radiation therapy due to endometrial cancer. The patient initially presented with postmenopausal bleeding. Cytology and biopsy of the endometrium were performed and endometrial adenosquamous carcinoma was diagnosed followed by radical hysterectomy and postoperative local radiatiotherapy (50 Gy). One year later patient presented with a great painful tumorous mass in the right breast. Physical examination revealed an oval tumor, located in upper and outer quadrant of the right breast, around 15 cm in diameter. Mammography and ultrasonography were performed. The angiosarcoma of the breast was confirmed by biopsy. The patient underwent radical mastectomy. Histopathology proved the diagnosis of angiosarcoma (high-grade, numerous mitoses over 10/10 HPF, necrosis, “blood lakes”, infiltrative borders). Differential diagnosis of a breast angiosarcoma should be considered in all painful breast tumours no mather the time and the location of the previous radiation treatment even if benign characteristics of these masses have been detected by mammography and breast ultrasound.

scholarly journals Small Cell Neuroendocrine Carcinoma of Tonsil – A Rare Occurrence

2020 ◽  
Vol 5 (6) ◽  
pp. 1-2
Author(s):  
Peoli Mukutawat ◽  
Bibhavendra Kumar Singh ◽  
Kunwar Prativyom
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Histopathological Examination ◽  
Tissue Sample ◽  
Small Cell ◽  
External Beam Radiation ◽  
Cervical Region ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Beam Radiation ◽  
Proliferative Growth ◽  
The Right

Small cell neuroendocrine carcinomas of tonsil are extremely rare cancers and only a few cases have been reported till date. They carry a poor prognosis. Paraneoplastic syndromes like SIADH, Cushing’s syndrome and Eaton-Lambert myasthenic syndrome can be found associated with these carcinomas. The tumor can metastasize to liver, lungs, bone, brain and skin. A 70-year-old male presented with a 2-month history of pain in throat which was moderate to severe in intensity and intermittent. Local examination of oropharynx revealed a 5×5 cm ulcero-proliferative growth over the right tonsil extending to right side of base of tongue, vallecula, and right retromolar trigone. Multiple matted lymph nodes were palpable in the right cervical region. Histopathological examination of tissue sample from the growth over the right tonsil revealed small cell neuroendocrine carcinoma. On immunohistochemistry, chromogranin and CD56 were positive. Patient received 2-courses of neoadjuvant chemotherapy with cisplatin and etoposide. Then the patient was planned for external beam radiation therapy with dose of 60 Gy in 30 fractions in 6 weeks. Small cell neuroendocrine carcinoma of tonsil are likely to be very aggressive with a tendency of developing early regional lymphatic and systemic metastases. More research and clinical trials shall be explored to obtain a standard treatment strategy for these patients.

Mortality and morbidity in long-term surviving patients treated with chemotherapy with or without irradiation for small-cell lung cancer.

1986 ◽  
Vol 4 (7) ◽  
pp. 1044-1052 ◽  
Author(s):  
K Osterlind ◽  
H H Hansen ◽  
M Hansen ◽  
P Dombernowsky
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cumulative Risk ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mortality And Morbidity ◽  
Disease Free ◽  
Risk Of Relapse

Mortality and morbidity was investigated in a consecutive series of 72 patients with small-cell lung cancer (SCLC) who were found to be disease-free at restaging after 18 months of treatment. These patients were all the long-term survivors among 874 patients included in one of six trials between 1973 and 1981. All studies used combination chemotherapy with or without irradiation. Follow-up of the patients varied between 4 and 11 years. The estimated 5-year survival rate subsequent to discontinuation of therapy was 0.24, corresponding to a death rate of 0.25 per year or ten times greater than the expected mortality for persons of the same age group. This high mortality was primarily related to recurrent SCLC, the estimated cumulative risk of relapse reaching 46% at the time of the latest recurrence 5 years from diagnosis. The risk of relapse was generally independent of the pretreatment disease stage although it was reduced in patients with resectable disease and was greater in those with pretreatment liver or bone marrow metastases. Equal risks of relapse were related to the use of regimens with and without radiotherapy. The cumulative risk of relapse in patients surviving 3 years from initiation of the treatment was less than 15% and accordingly, 3 years of follow-up seems sufficient for comparison of long-term results obtained in different trials. The second factor resulting in death or disease was second cancer, for which the cumulated risk increased to 32%, the latest occurring 5.4 years from the diagnosis of SCLC. Five of these cases were non-small-cell lung cancers and three were secondary leukemias. The estimated mortality related to non-neoplastic conditions was just significantly greater than expected. In spite of the increased mortality in this series, 38 of 54 2-year disease-free survivors and 20 of 22 5-year survivors resumed a lifestyle similar to that before diagnosis of SCLC.

Clinical and molecular characteristics of non-small cell lung cancer patients from rural Maine.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18237-e18237
Author(s):  
Antoine Harb ◽  
Adam Curtis ◽  
Laura Skacel ◽  
Michael Babcock ◽  
Marek Skacel
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Early Stage ◽  
P53 Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Early Stage Disease ◽  
Stage Disease ◽  
Disease Free

e18237 Background: Non-Small Cell Lung Cancer (NSCLC) is the most common malignancy worldwide and the leading cause of malignancy-related mortality in the United States. The state of Maine in particular, has one of the highest rates of lung cancer in the country. Methods: We reviewed all NSCLC patients (adenocarcinoma (AC) and squamous cell (SC) histology) diagnosed between January 2017 and June 2018 at Northern Light Cancer Institute. 261 patients with clinical follow-up were identified. We correlated their clinical characteristics with molecular abnormalities identified by Next Generation Sequencing (NGS) and Fluorescence in situ hybridization, PD-L1 status by immunohistochemistry, disease-free and overall survival. Results: 210 patients had AC and 51 SC. They were evenly split between men and women. The median age at diagnosis was 68 years. 99% of patients were Caucasian. 15 patients were never smokers, the rest were equally divided between active and previous smokers. 44% had early stage disease (I/II) and 56% had late stage disease (III/IV) on presentation. 36.4% had a PD-L1 high status. The frequencies of the molecular aberrations identified in AC and SC are listed in the table below: Treatment differed by stage, including surgery/Radiation +/- adjuvant chemotherapy for early stage disease, definitive chemo-radiation followed by immunotherapy for stage III disease. Stage IV patients were treated with immunotherapy, combination chemo-immunotherapy, targeted therapy, palliative radiation and hospice referral. After a median follow-up of 10.6 months, overall survival (OS) was 66%. Disease free survival (DFS) was 33%. Using univariate (chi-square), multivariate (logistic regression) and Kaplan-Meier (log rank) analyses, we identified that in addition to a high clinical stage, which was associated with shorter OS and DFS, high PD-L1 status, and the presence of p53 mutation, were independent predictors of shorter OS, and p53 mutation of shorter DFS. Conclusions: NGS-based molecular testing deployed in real-time non-academic setting proved to be a valuable tool to identify therapeutic and prognostic targets in NSCLC. Besides those endorsed by the NCCN guidelines, p53 mutation is a common abnormality associated with adverse outcomes. While high PD-L1 expression is a desirable immunotherapy marker, its presence also predicted adverse overall outcomes in our patients.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document